Gilead Sciences (GILD) Raw Materials (2009 - 2015)
Gilead Sciences (GILD) posted Raw Materials of $1.3 billion for Q4 2015, up 46.53% quarter-over-quarter from $909.0 million in Q4 2014, and up 46.53% year-on-year from $909.0 million in Q4 2014.
Gilead Sciences (GILD) Raw Materials (2009 - 2015) Analysis & Trends
Gilead Sciences (GILD) has reported Raw Materials for 7 consecutive years, with $1.3 billion the latest figure, recorded in Q4 2015.
- Raw Materials for Q4 2015 came in at $1.3 billion, up 46.53% year-over-year; the trailing twelve-month figure through Dec 2015 was $1.3 billion (up 46.53% YoY), and the FY2015 annual result was $1.3 billion, up 46.53% from the prior year.
- Raw Materials was $1.3 billion for Q4 2015 at Gilead Sciences, up from $909.0 million in the prior quarter.
- Over five years, Raw Materials peaked at $1.3 billion in Q4 2015 and troughed at $559.2 million in Q1 2011.
- Average Raw Materials over 5 years is $872.3 million, with a median of $866.4 million recorded in 2011.
- Year-over-year, Raw Materials jumped 96.23% in 2011 and declined 13.38% in 2014.
- Over 5 years, Raw Materials stood at $697.6 million in 2011, then rose by 18.48% to $826.5 million in 2012, then advanced by 26.96% to $1.0 billion in 2013, then slipped by 13.38% to $909.0 million in 2014, then soared by 46.53% to $1.3 billion in 2015.
- Per Business Quant data, the three most recent Raw Materials figures were $1.3 billion in Q4 2015, $909.0 million in Q4 2014, and $944.9 million in Q2 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 1.33 Bn |
| Dec 31, 2014 | 909.00 Mn |
| Jun 30, 2014 | 944.89 Mn |
| Dec 31, 2013 | 1.05 Bn |
| Dec 31, 2012 | 826.55 Mn |
| Dec 31, 2011 | 697.62 Mn |
| Sep 30, 2011 | 866.41 Mn |
| Jun 30, 2011 | 665.25 Mn |
| Mar 31, 2011 | 559.16 Mn |
| Dec 31, 2010 | 408.02 Mn |
| Sep 30, 2010 | 441.53 Mn |
| Dec 31, 2009 | 333.58 Mn |